Health

Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy

* RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation study. * Monotherapy clinical efficacy was observed in HR+/HER2- advanced breast cancer (ABC) patients who have progressed on CDK4/6 inhibitors (CDK4/6is) and ...

2023-12-08 07:39 1861

AMAZFIT LAUNCHES NEW SPECIAL EDITIONS OF AMAZFIT BALANCE, AND PARTNERS WITH NON-PROFIT ONE TREE PLANTED TO SUPPORT REFORESTATION PROJECTS IN EUROPE

MILPITAS, Calif., Dec. 7, 2023 /PRNewswire/ -- Amazfit , a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has today unveiled four Special Edition colors of the Amazfit Balance. Along with names inspired by the harmon...

2023-12-08 00:00 2136

2023 SABCS - TransThera announces an oral presentation of tinengotinib clinical data in breast cancer

NANJING, China, Dec. 7, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announced that an oral presentation of tinengotinib clinical data in breast cancer was delivered at 202...

2023-12-07 21:00 1384

CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum

NANJING, China, Dec. 7, 2023 /PRNewswire/ -- The rapid advancement of technology has propelled the field of life sciences into unprecedented growth, constantly expanding our understanding and imagination. Particularly in the field of cellular gene therapy, a series of recent positive developments...

2023-12-07 19:25 1580

Waterdrop Inc. Announces Third Quarter 2023 Unaudited Financial Results

BEIJING, Dec. 7, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the third quarter ended September 3...

2023-12-07 17:00 3614

IonOpticks and Newomics broaden chromatography accessibility for Agilent mass specs, with Shimadzu pending

MELBOURNE, Australia, Dec. 6, 2023 /PRNewswire/ -- IonOpticks, the world leader in high performance liquid chromatography for mass spectrometry, is proud to announce an exciting collaboration with Newomics Inc. that has produced an interface solution for their flagship Aurora Series columns and A...

2023-12-07 07:04 1639

GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant

Starts undertaking quality evaluation and characterization of iPSCs in accordance with ISO standards PALO ALTO, Calif., Dec. 6, 2023 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com ), specializing in induced pluripotent stem cells (iPSCs) and ...

2023-12-06 22:30 1500

Lixiang Education Receives Nasdaq Extension to Regain $1 Bid Price Compliance

LISHUI, China, Dec. 6, 2023 /PRNewswire/ -- Lixiang Education Holding Co., Ltd. (the "Company" or NASDAQ: LXEH), a prestigious private education service provider inChina, today announced that on November 30, 2023, it received a letter from the Nasdaq Hearings Panel (the "Panel"), indicating the P...

2023-12-06 19:00 3664

WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader

SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced it has successfully passed an on-site GMP audit by a global vaccine leader at its first standalone CDMO site in Suzhou,China. The audit m...

2023-12-06 17:00 1590

GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia

* To commence operation by 2027…with max. 400K liters of plasma production capacity per annum * The first step towards localization of Indonesia's critical medical product YONGIN,South Korea, Dec. 5, 2023 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, announced onDece...

2023-12-06 08:56 1848

The 2023 Investor Open Day of Zylox-Tonbridge was successfully held

HANGZHOU, China, Dec. 5, 2023 /PRNewswire/ -- On November 29th, the 2023 Investor Open Day of Zylox-Tonbridge ("2190. HK", hereinafter referred to as "the Company") was successfully held in Hangzhou, China. The event attracted more than 200 online and offline investors and securities analysts wo...

2023-12-05 22:22 4049

Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023

First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023  /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of its bispecific IO drug, cadonilimab (a PD-1/CTLA-4...

2023-12-05 21:00 1417

inQB8 Medical Technologies LLC and Peijia Medical Limited Report Successful First-in-Human (FIH) Implantation of MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System in The United States of America

WINCHESTER, Mass. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ -- inQB8 Medical Technologies LLC (inQB8), in partnership with Peijia Medical Limited (Peijia, (9996.HK)),announced that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve (TTV) in a patient suffering from torrenti...

2023-12-05 21:00 1914

J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023

SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held inSingapore from 1st to 3rd December 2023.

2023-12-05 15:16 1382

Ubie's AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships

Ubie, a trailblazing AI-driven healthcare company, has achieved a new milestone with its AI Symptom Checker, surpassing 2 million uses in the U.S. in just over a year. Leveraging this expanding user engagement, Ubie is advancing its partnerships with pharmaceutical companies to promote early dise...

2023-12-05 00:00 1494

Pioneering health innovations at China Int'l Supply Chain Expo

BEIJING, Dec. 4, 2023 /PRNewswire/ -- This is a report from China.org.cn about health innovations at China Int'l Supply Chain Expo:   At a dental clinic at the China Int'l Supply Chain Expo, you can take advantage of a free dental check. The 360° view allows you to see all a...

2023-12-04 22:20 1470

CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia

SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration (FDA) has granted Investiga...

2023-12-04 21:50 1395

Technoderma Medicines Completes Phase 1 Dose Escalation Clinical Trial of TDM-180935 for Atopic Dermatitis

CHENGDU, China, Dec. 4, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment for Atopic Dermatitis (AD). This first cl...

2023-12-04 21:13 1347

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt,Germany. Under the terms of the agreement, Merck will be granted an exclusive licens...

2023-12-04 21:05 1418

Crystal Pharmatech's CDMO Business Unit successfully passed the dual certification of GMP and GDP conducted by SGS

SUZHOU, China, Dec. 4, 2023 /PRNewswire/ -- Recently, Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services (CFS) successfully obtained dual certification in Good Manufacturing Practices (GMP)[1] and Good Distribution Practices (GDP)[2] from SGS, an internationally recognized thi...

2023-12-04 21:00 1174
1 ... 57585960616263 ... 279